Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Single-Center, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of Intravenous DTRI-031 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Single-Center, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of Intravenous DTRI-031 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTRI-031 (Primary)
  • Indications Stroke
  • Focus Adverse reactions; First in man
  • Sponsors Basking Biosciences

    • Most Recent Events

    • 10 Feb 2023 Results (n=40) presented at the International Stroke Conference 2023.
    • 09 Feb 2023 Results published in the Basking Biosciences media release.
    • 31 Jan 2023 According to a Basking Biosciences media release, data will be presented at the American Heart Associations 2023 International Stroke Conference (ISC) 2023 held in Dallas, Texas from 8-10th February.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top